Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome.

Beksac M, Cengiz Seval G, Kanellias N, Coriu D, Rosiñol L, Ozet G, Goranova-Marinova V, Unal A, Bila J, Ozsan H, Ivanaj A, Balić LI, Kastritis E, Bladé J, Dimopoulos MA.

Haematologica. 2019 Jul 5. pii: haematol.2019.219295. doi: 10.3324/haematol.2019.219295. [Epub ahead of print]

2.

Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome.

Trakada G, Kastritis E, Gavriatopoulou M, Velentza L, Fotiou D, Ziogas DC, Panagiotidis I, Eleutherakis-Papaiakovou E, Roussou M, Migkou M, Kanellias N, Ntanasis-Stathopoulos I, Kallianos A, Terpos E, Dimopoulos MA.

Ann Hematol. 2019 Jun;98(6):1427-1434. doi: 10.1007/s00277-019-03641-x. Epub 2019 Mar 5.

PMID:
30834954
3.

Toll-Like Receptor 4 Activation Promotes Multiple Myeloma Cell Growth and Survival Via Suppression of The Endoplasmic Reticulum Stress Factor Chop.

Bagratuni T, Sklirou AD, Kastritis E, Liacos CI, Spilioti C, Eleutherakis-Papaiakovou E, Kanellias N, Gavriatopoulou M, Terpos E, Trougakos IP, Dimopoulos MA.

Sci Rep. 2019 Mar 1;9(1):3245. doi: 10.1038/s41598-019-39672-7.

4.

Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group.

Bustoros M, Kastritis E, Sklavenitis-Pistofidis R, Liu CJ, Hornburg K, Kanellias N, Kim G, Liu D, Gavriatopoulou M, Marinac CR, Roussou M, Migkou M, Noonan K, Reyes K, Rivotto B, Neuse CJ, Ziogas DC, Laubach J, Terpos E, Anderson KC, Richardson PG, Ghobrial IM, Dimopoulos MA.

Am J Hematol. 2019 May;94(5):E146-E149. doi: 10.1002/ajh.25441. Epub 2019 Mar 6. No abstract available.

PMID:
30773670
5.

Denosumab effects on serum levels of the bone morphogenetic proteins antagonist noggin in patients with transfusion-dependent thalassemia and osteoporosis.

Voskaridou E, Ntanasis-Stathopoulos I, Christoulas D, Sonnleitner L, Papaefstathiou A, Dimopoulou M, Missbichler A, Kanellias N, Repa K, Papatheodorou A, Peppa M, Hawa G, Terpos E.

Hematology. 2019 Dec;24(1):318-324. doi: 10.1080/16078454.2019.1570617.

PMID:
30665323
6.

Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis.

Kastritis E, Gavriatopoulou M, Roussou M, Bagratuni T, Migkou M, Fotiou D, Ziogas DC, Kanellias N, Eleutherakis-Papaiakovou E, Dialoupi I, Ntanasis-Stathopoulos I, Spyropoulou-Vlachou M, Psimenou E, Gakiopoulou H, Marinaki S, Papadopoulou E, Ntalianis A, Terpos E, Dimopoulos MA.

Amyloid. 2018 Dec;25(4):234-241. doi: 10.1080/13506129.2018.1540410. Epub 2019 Jan 20.

PMID:
30663408
7.

Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients.

Gavriatopoulou M, Fotiou D, Koloventzou U, Roussou M, Migkou M, Ntanasis-Stathopoulos I, Kanellias N, Ziogas DC, Panagiotidis I, Gika D, Eleutherakis-Papaiakovou E, Terpos E, Kastritis E, Dimopoulos MA.

Leuk Lymphoma. 2019 Mar;60(3):619-628. doi: 10.1080/10428194.2018.1509323. Epub 2019 Jan 10.

PMID:
30628505
8.

Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates.

Terpos E, Kastritis E, Ntanasis-Stathopoulos I, Christoulas D, Papatheodorou A, Eleutherakis-Papaiakovou E, Kanellias N, Fotiou D, Ziogas DC, Migkou M, Roussou M, Trougakos IP, Gavriatopoulou M, Dimopoulos MA.

Am J Hematol. 2019 Apr;94(4):400-407. doi: 10.1002/ajh.25392. Epub 2019 Jan 10.

PMID:
30592079
9.

Management of multiple myeloma bone disease: impact of treatment on renal function.

Kanellias N, Gavriatopoulou M, Terpos E, Dimopoulos MA.

Expert Rev Hematol. 2018 Nov;11(11):881-888. doi: 10.1080/17474086.2018.1531702. Epub 2018 Oct 20. Review.

PMID:
30285492
10.

Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM.

Gavriatopoulou M, Terpos E, Ntanasis-Stathopoulos I, Papasotiriou I, Fotiou D, Migkou M, Roussou M, Kanellias N, Ziogas D, Dialoupi I, Eleutherakis Papaiakovou E, Kastritis E, Dimopoulos MA.

Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):23-28. doi: 10.1016/j.clml.2018.07.294. Epub 2018 Aug 23.

PMID:
30224328
11.

Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies.

Bagratuni T, Ntanasis-Stathopoulos I, Gavriatopoulou M, Mavrianou-Koutsoukou N, Liacos C, Patseas D, Kanellias N, Migkou M, Ziogas DC, Eleutherakis-Papaiakovou E, Roussou M, Fotiou D, Terpos E, Kastritis E, Dimopoulos MA.

Leukemia. 2018 Dec;32(12):2617-2625. doi: 10.1038/s41375-018-0197-7. Epub 2018 Jul 19.

12.

Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis.

Kastritis E, Kostopoulos IV, Terpos E, Paiva B, Fotiou D, Gavriatopoulou M, Kanellias N, Ziogas DC, Roussou M, Migkou M, Eleutherakis-Papaiakovou E, Trougakos IP, Tsitsilonis O, Dimopoulos MA.

Blood Cancer J. 2018 May 24;8(5):46. doi: 10.1038/s41408-018-0086-3. No abstract available.

13.

Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma.

Terpos E, Ntanasis-Stathopoulos I, Christoulas D, Bagratuni T, Bakogeorgos M, Gavriatopoulou M, Eleutherakis-Papaiakovou E, Kanellias N, Kastritis E, Dimopoulos MA.

Blood Cancer J. 2018 May 11;8(5):42. doi: 10.1038/s41408-018-0075-6.

14.

Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia.

Eleutherakis-Papaiakovou E, Kastritis E, Gavriatopoulou M, Christoulas D, Roussou M, Ntanasis-Stathopoulos I, Kanellias N, Papatheodorou A, Dimopoulos MA, Terpos E.

Clin Lymphoma Myeloma Leuk. 2018 Jun;18(6):431-437. doi: 10.1016/j.clml.2018.03.010. Epub 2018 Mar 31.

PMID:
29685422
15.

Cardiac and renal complications of carfilzomib in patients with multiple myeloma.

Dimopoulos MA, Roussou M, Gavriatopoulou M, Psimenou E, Ziogas D, Eleutherakis-Papaiakovou E, Fotiou D, Migkou M, Kanellias N, Panagiotidis I, Ntalianis A, Papadopoulou E, Stamatelopoulos K, Manios E, Pamboukas C, Kontogiannis S, Terpos E, Kastritis E.

Blood Adv. 2017 Feb 27;1(7):449-454. doi: 10.1182/bloodadvances.2016003269. eCollection 2017 Feb 28.

16.

The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents.

Gavriatopoulou M, Kastritis E, Ntanasis-Stathopoulos I, Fotiou D, Roussou M, Migkou M, Ziogas DC, Kanellias N, Terpos E, Dimopoulos MA.

Blood. 2018 Jan 25;131(4):464-467. doi: 10.1182/blood-2017-10-809293. Epub 2017 Nov 22. No abstract available.

17.

Low circulating mannan-binding lectin levels correlate with increased frequency and severity of febrile episodes in myeloma patients who undergo ASCT and do not receive antibiotic prophylaxis.

Eleutherakis-Papaiakovou E, Dimopoulos MA, Kastritis E, Christoulas D, Roussou M, Migkou M, Gavriatopoulou M, Fotiou D, Panagiotidis I, Ziogas DC, Kanellias N, Papadimitriou C, Terpos E.

Bone Marrow Transplant. 2017 Nov;52(11):1537-1542. doi: 10.1038/bmt.2017.172. Epub 2017 Aug 14.

PMID:
28805791
18.

Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases.

Ziogas DC, Terpos E, Gavriatopoulou M, Migkou M, Fotiou D, Roussou M, Kanellias N, Tatouli I, Eleutherakis-Papaiakovou E, Panagiotidis I, Ntanasis-Stathopoulos I, Kastritis E, Dimopoulos MA.

Leuk Lymphoma. 2018 Apr;59(4):983-987. doi: 10.1080/10428194.2017.1361031. Epub 2017 Aug 7. No abstract available.

PMID:
28782413
19.

Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit.

Dimopoulos MA, Roussou M, Gavriatopoulou M, Fotiou D, Ziogas DC, Migkou M, Panagiotidis I, Eleutherakis-Papaiakovou E, Kanellias N, Psimenou E, Marinaki S, Bacharaki D, Mparmparoussi D, Matsouka C, Giannouli S, Terpos E, Kastritis E.

Blood Cancer J. 2017 Jun 16;7(6):e571. doi: 10.1038/bcj.2017.49. No abstract available.

20.

Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib.

Kastritis E, Gavriatopoulou M, Roussou M, Fotiou D, Ziogas DC, Migkou M, Eleutherakis-Papaiakovou E, Panagiotidis I, Kanellias N, Psimenou E, Papadopoulou E, Pamboucas C, Manios E, Gakiopoulou H, Ntalianis A, Tasidou A, Giannouli S, Terpos E, Dimopoulos MA.

Blood Cancer J. 2017 Jun 16;7(6):e570. doi: 10.1038/bcj.2017.47.

21.

Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy.

Kastritis E, Gavriatopoulou M, Roussou M, Migkou M, Fotiou D, Ziogas DC, Kanellias N, Eleutherakis-Papaiakovou E, Panagiotidis I, Giannouli S, Psimenou E, Marinaki S, Apostolou T, Gakiopoulou H, Tasidou A, Papassotiriou I, Terpos E, Dimopoulos MA.

Am J Hematol. 2017 Jul;92(7):632-639. doi: 10.1002/ajh.24738. Epub 2017 May 26.

22.

High levels of periostin correlate with increased fracture rate, diffuse MRI pattern, abnormal bone remodeling and advanced disease stage in patients with newly diagnosed symptomatic multiple myeloma.

Terpos E, Christoulas D, Kastritis E, Bagratuni T, Gavriatopoulou M, Roussou M, Papatheodorou A, Eleutherakis-Papaiakovou E, Kanellias N, Liakou C, Panagiotidis I, Migkou M, Kokkoris P, Moulopoulos LA, Dimopoulos MA.

Blood Cancer J. 2016 Oct 7;6(10):e482. doi: 10.1038/bcj.2016.90.

23.

Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment.

Terpos E, Migkou M, Christoulas D, Gavriatopoulou M, Eleutherakis-Papaiakovou E, Kanellias N, Iakovaki M, Panagiotidis I, Ziogas DC, Fotiou D, Kastritis E, Dimopoulos MA.

Blood Cancer J. 2016 May 27;6:e428. doi: 10.1038/bcj.2016.37.

24.

Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma.

Zagouri F, Roussou M, Kastritis E, Gavriatopoulou M, Eleutherakis-Papaiakovou E, Kanellias N, Kalapanida D, Christoulas D, Migkou M, Terpos E, Dimopoulos MA.

Leuk Lymphoma. 2016 Aug;57(8):1776-80. doi: 10.3109/10428194.2016.1151513. Epub 2016 Feb 25.

PMID:
26916452
25.

Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo staging.

Kastritis E, Gavriatopoulou M, Dimopoulos MA, Eleutherakis-Papaiakovou E, Kanellias N, Roussou M, Pamboucas C, Toumanidis ST, Terpos E.

Blood Cancer J. 2015 Jun 5;5:e319. doi: 10.1038/bcj.2015.45.

26.

VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT.

Terpos E, Christoulas D, Kastritis E, Roussou M, Migkou M, Eleutherakis-Papaiakovou E, Gavriatopoulou M, Gkotzamanidou M, Kanellias N, Manios E, Papadimitriou C, Dimopoulos MA.

Leukemia. 2014 Apr;28(4):928-34. doi: 10.1038/leu.2013.267. Epub 2013 Sep 18.

PMID:
24045498
27.

Decreased incidence of EPCR 4678G/C SNP in multiple myeloma patients with thrombosis.

Dri AP, Politou M, Gialeraki A, Bagratuni T, Kanellias N, Terpos E.

Thromb Res. 2013 Sep;132(3):400-1. doi: 10.1016/j.thromres.2013.07.024. Epub 2013 Aug 8. No abstract available.

PMID:
23993723
28.

Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma.

Terpos E, Kanellias N, Christoulas D, Kastritis E, Dimopoulos MA.

Onco Targets Ther. 2013 May 10;6:531-8. doi: 10.2147/OTT.S34498. Print 2013.

29.

Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease.

Kastritis E, Terpos E, Moulopoulos L, Spyropoulou-Vlachou M, Kanellias N, Eleftherakis-Papaiakovou E, Gkotzamanidou M, Migkou M, Gavriatopoulou M, Roussou M, Tasidou A, Dimopoulos MA.

Leukemia. 2013 Apr;27(4):947-53. doi: 10.1038/leu.2012.309. Epub 2012 Nov 6.

PMID:
23183429
30.

Tobacco smoking and risk of multiple myeloma: a meta-analysis of 40 observational studies.

Psaltopoulou T, Sergentanis TN, Kanellias N, Kanavidis P, Terpos E, Dimopoulos MA.

Int J Cancer. 2013 May 15;132(10):2413-31. doi: 10.1002/ijc.27898. Epub 2012 Oct 29.

31.

Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy.

Terpos E, Kastritis E, Christoulas D, Gkotzamanidou M, Eleutherakis-Papaiakovou E, Kanellias N, Papatheodorou A, Dimopoulos MA.

Ann Oncol. 2012 Oct;23(10):2681-6. Epub 2012 Apr 6.

PMID:
22492699

Supplemental Content

Loading ...
Support Center